Kasi: The overall response rate and the reported side effects don’t necessarily encompass the tangible impact that we're ...
Morning Overview on MSN
Daraxonrasib, a daily RAS-blocking pill, raised pancreatic cancer survival from 6.7 to 13.2 months with fewer severe side effects than chemo
Patients with metastatic pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...
A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...
Morning Overview on MSN
A daily pancreatic cancer pill nearly doubled survival time from 6.7 months to 13.2 months in a 500-person trial
Patients with advanced pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...
LONDON, England—Clinicians can’t go wrong whether they continue or discontinue renin-angiotensin-system (RAS) inhibitors before noncardiac surgery, the Stop-or-Not trial suggests. The rate of ...
LONDON -- No blanket statement could be made regarding whether patients undergoing noncardiac surgery should continue or withdraw their renin-angiotensin system (RAS) inhibitor therapy based on the ...
3d
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention
Oncolytics Biotech (ONCY) is back on investors’ radars after early preclinical results showed its immunotherapy pelareorep combined with RAS inhibitors produced stronger anti tumor activity than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results